Plate Nº 80 · recorded November 18, 2026

Health & Medicine ResearchReported finding

Medicaid weight loss drug prescriptions fell 84% after coverage cuts

Prescriptions for GLP-1 weight loss drugs in four Medicaid programs fell from 2,914 to 421 per 100,000 members after coverage ended on January 1, 2026, a JAMA study finds.

By Priya Raman3 min read686 words

In brief

  1. Medicaid prescriptions for GLP-1 weight loss drugs fell from 2,914 per 100,000 members in late 2025 to 421 per 100,000 in the first three months of 2026 in California, New Hampshire, Pennsylvania and South Carolina.
  2. After comparing with ten states that kept coverage, the researchers estimated an 84% drop associated with the coverage cuts.
  3. Pennsylvania saw the largest decrease, followed by New Hampshire, California and South Carolina.
  4. Roughly 175,500 to 526,600 fewer people may have filled these prescriptions in the four states, a range the team describes as uncertain.
  5. The study, published in JAMA on November 16, 2026, used Medicaid records dating back to 2022 and did not measure changes in body weight or health.
Weight loss drug access plunges after states end Medicaid coverage
Plate Nº 80Weight loss drug access plunges after states end Medicaid coverage — Pexels / pixabay

Medicaid prescriptions for GLP-1 weight loss drugs fell by an estimated 84% in the four states that ended coverage on January 1, 2026, according to an analysis published in JAMA on November 16, 2026.

The analysis, from researchers at the University of Pittsburgh, documents a shift that took place inside a single quarter. Prescriptions in California, New Hampshire, Pennsylvania and South Carolina dropped from 2,914 per 100,000 Medicaid members in the last three months of 2025 to 421 per 100,000 in the first three months of 2026.

Ten states that kept coverage recorded a much smaller decline. After accounting for that comparison group, the researchers attributed about 84% of the change to the coverage cuts.

For anyone collecting a refill, a state policy decision arrives as a refusal at the pharmacy counter. The medicine itself does not change; the rules about who pays for it do, and in these four states they changed overnight.

GLP-1 drugs are a class of medicines that copy the action of a hormone released in the gut, reducing hunger; some versions are also prescribed for diabetes. Unlike most prescription drugs, weight loss medicines are optional coverage for state Medicaid programs, which jointly fund health insurance for many people with low incomes. That optional status is what turns an administrative ruling into a supply problem for patients already taking the medication.

What changed on January 1, 2026?

California, New Hampshire, Pennsylvania and South Carolina stopped covering GLP-1 medicines prescribed for weight loss on January 1, 2026. The researchers examined Medicaid records from across the country, dating back to 2022, to see what happened immediately afterward.

  • Prescriptions per 100,000 Medicaid members: 2,914 in the last three months of 2025.
  • Prescriptions per 100,000 Medicaid members: 421 in the first three months of 2026.
  • Comparison group: ten states that continued covering the drugs and showed a much smaller decline.
  • Estimated change after adjusting for that comparison: a drop of about 84%.

The researchers said the results raise concerns about interruptions to ongoing treatment. Weight loss medicines generally have to be taken over time to maintain their benefits, so a break in coverage can complicate weight management for people who had already stabilized on the drug.

Which states were hardest hit?

Pennsylvania recorded the largest decrease, followed by New Hampshire, California and South Carolina.

The team also estimated that roughly 175,500 to 526,600 fewer people may have filled these prescriptions across the four states. The range is wide because one person can fill several prescriptions, and some patients may have paid for their medicine themselves rather than stopping it.

Did patients switch to diabetes versions?

That was the first alternative explanation the researchers checked, and the data did not support it. Medicaid prescriptions for the diabetes-labeled versions of these drugs — the same class of medicines prescribed for diabetes rather than for weight loss — showed no meaningful overall rise, although the researchers could not track individual patients' choices.

What did the study not measure?

The analysis examined prescription patterns rather than running a controlled experiment, so other policy changes may have played a part. It also did not measure changes in body weight or health after coverage stopped, which leaves the clinical consequences of the drop unknown from this study alone.

The strongest argument for reading the decline as a direct effect of coverage, the researchers note, is timing: the fall began immediately and was far larger than in states that kept coverage. The practical distinction matters as much. The pattern resembles a supply line being cut off rather than a patient choosing to stop, and that is what separates a coverage decision from a treatment decision.

Why does access matter as much as efficacy?

The broader message of the study is that access to treatment depends not only on whether a medicine works, but also on whether people can afford to keep taking it. For patients on long-term weight loss therapy, the question after January 1 was less about the evidence for the drug than about who would pay for the next refill.

via knowridge.com (Source)

Filed under

  • medicaid
  • glp-1-medications
  • obesity-treatment
  • health-policy
  • prescription-access
Share this article:

More from Priya Raman

Priya Raman

Show full bio

Senior reporter covering people, launches and day-to-day practice in general science news at SciBeat.

476 articles

Nearby plates

« Previous article